• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Monte Carlo simulations to meet the ESC recommended low-density lipoprotein cholesterol targets.

作者信息

Deo Salil V

机构信息

Surgical Services, Louis Stokes Cleveland VA Medical Center, Cleveland, USA.

Case School of Medicine, Case Western Reserve University, Cleveland, USA.

出版信息

Lancet Reg Health Eur. 2023 Jun 16;31:100670. doi: 10.1016/j.lanepe.2023.100670. eCollection 2023 Aug.

DOI:10.1016/j.lanepe.2023.100670
PMID:37388944
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10300384/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e35/10300384/48e507f3ba9a/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e35/10300384/48e507f3ba9a/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e35/10300384/48e507f3ba9a/gr1.jpg

相似文献

1
Monte Carlo simulations to meet the ESC recommended low-density lipoprotein cholesterol targets.蒙特卡洛模拟以达到欧洲心脏病学会推荐的低密度脂蛋白胆固醇目标。
Lancet Reg Health Eur. 2023 Jun 16;31:100670. doi: 10.1016/j.lanepe.2023.100670. eCollection 2023 Aug.
2
Evaluation and Development of Vancomycin Dosing Schemes to Meet New AUC/MIC Targets in Intermittent Hemodialysis Using Monte Carlo Simulation Techniques.利用蒙特卡罗模拟技术评估和制定万古霉素剂量方案，以满足间歇性血液透析中新的 AUC/MIC 目标。
J Clin Pharmacol. 2021 Feb;61(2):211-223. doi: 10.1002/jcph.1727. Epub 2020 Aug 26.
3
Population Effect of Differences in Cholesterol Guidelines in Eastern Europe and the United States.东欧和美国胆固醇指南差异的人群效应。
JAMA Cardiol. 2016 Sep 1;1(6):700-7. doi: 10.1001/jamacardio.2016.1585.
4
Dyslipidaemia management in the cardiac rehabilitation clinic of a tertiary referral centre: analysis of the impact of new ESC guidance on LDL-C target achievement.在一家三级转诊中心的心脏康复诊所进行血脂异常管理：新 ESC 指南对 LDL-C 目标达标影响的分析。
Ir J Med Sci. 2022 Dec;191(6):2569-2577. doi: 10.1007/s11845-021-02885-9. Epub 2022 Jan 15.
5
Lipid-cholesterol interactions. Monte Carlo simulations and theory.脂质-胆固醇相互作用。蒙特卡洛模拟与理论
Biophys J. 1991 Feb;59(2):445-55. doi: 10.1016/S0006-3495(91)82238-X.
6
Achievement of the ESC recommendations for secondary prevention of cardiovascular risk factors in high-risk patients with type 2 diabetes: A real-world national cohort analysis.2型糖尿病高危患者心血管危险因素二级预防中欧洲心脏病学会（ESC）建议的达成情况：一项全国性真实世界队列分析
Int J Cardiol. 2023 Apr 15;377:104-111. doi: 10.1016/j.ijcard.2023.02.004. Epub 2023 Feb 9.
7
Investigation of Monte Carlo simulations of the electron transport in external magnetic fields using Fano cavity test.基于 Fano 腔测试的电子在外加磁场中输运的蒙特卡罗模拟研究。
Z Med Phys. 2023 Nov;33(4):499-510. doi: 10.1016/j.zemedi.2022.07.002. Epub 2022 Aug 25.
8
Monte Carlo calculation of monitor unit for electron arc therapy.电子弧形治疗的监测单位的蒙特卡罗计算。
Med Phys. 2010 Apr;37(4):1571-8. doi: 10.1118/1.3359819.
9
The need for PCSK9 inhibitors and associated treatment costs according to the 2019 ESC dyslipidaemia guidelines vs. the risk-based allocation algorithm of the 2017 ESC consensus statement: a simulation study in a contemporary CAD cohort.根据 2019 ESC 血脂异常指南与 2017 ESC 共识声明的风险分配算法相比，PCSK9 抑制剂的需求和相关治疗费用：当代 CAD 队列的模拟研究。
Eur J Prev Cardiol. 2021 Mar 23;28(1):47-56. doi: 10.1093/eurjpc/zwaa088.
10
Empirical investigations into Kruskal-Wallis power studies utilizing Bernstein fits, simulations and medical study datasets.利用伯恩斯坦拟合、模拟和医学研究数据集对 Kruskal-Wallis 功效研究的实证调查。
Sci Rep. 2023 Feb 9;13(1):2352. doi: 10.1038/s41598-023-29308-2.

本文引用的文献

1
Optimal implementation of the 2019 ESC/EAS dyslipidaemia guidelines in patients with and without atherosclerotic cardiovascular disease across Europe: a simulation based on the DA VINCI study.2019年欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常指南在欧洲有和没有动脉粥样硬化性心血管疾病患者中的最佳实施：基于达芬奇研究的模拟分析
Lancet Reg Health Eur. 2023 Jun 8;31:100665. doi: 10.1016/j.lanepe.2023.100665. eCollection 2023 Aug.
2
An estimation of the consequences of reinforcing the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society guidelines on current lipid-lowering treatment in patients with type 2 diabetes in tertiary care-a SwissDiab study.强化2016年和2019年欧洲心脏病学会/欧洲动脉粥样硬化学会指南对三级医疗中2型糖尿病患者当前降脂治疗的影响评估——一项瑞士糖尿病研究
Eur J Prev Cardiol. 2023 Oct 10;30(14):1473-1481. doi: 10.1093/eurjpc/zwad178.
3
Disparities in PCSK9 Initiation Among US Veterans with Peripheral Arterial Disease or Cerebrovascular Disease.美国外周动脉疾病或脑血管疾病患者中 PCSK9 起始治疗的差异。
Am J Cardiovasc Drugs. 2023 May;23(3):311-321. doi: 10.1007/s40256-023-00576-7. Epub 2023 Mar 22.
4
Lipid Lowering in "Very High Risk" Patients Undergoing Coronary Artery Bypass Surgery and Its Projected Reduction in Risk for Recurrent Vascular Events: A Monte Carlo Stepwise Simulation Approach.接受冠状动脉搭桥手术的“极高风险”患者的降脂治疗及其对复发性血管事件风险的预测降低：蒙特卡洛逐步模拟方法
J Cardiovasc Pharmacol. 2023 Feb 1;81(2):120-128. doi: 10.1097/FJC.0000000000001374.
5
Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study.全球心血管疾病负担及危险因素, 1990-2019:来自 GBD 2019 研究的更新。
J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021. doi: 10.1016/j.jacc.2020.11.010.
6
Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study.2019 年 ESC/EAS 血脂异常指南在近期心肌梗死患者全国数据中的应用：一项模拟研究。
Eur Heart J. 2020 Oct 21;41(40):3900-3909. doi: 10.1093/eurheartj/ehaa034.
7
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.2019年欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理指南：通过血脂修饰降低心血管风险
Eur Heart J. 2020 Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455.
8
PCSK9 Inhibitors Prior Authorization.前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂的预先授权
Circ Cardiovasc Qual Outcomes. 2019 Aug;12(8):e005910. doi: 10.1161/CIRCOUTCOMES.119.005910. Epub 2019 Jul 23.
9
The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial.在 IMPROVE-IT 试验中，对于既往行冠状动脉旁路移植术和急性冠状动脉综合征的患者，加用依折麦布联合他汀类药物治疗的获益。
Eur Heart J. 2016 Dec 21;37(48):3576-3584. doi: 10.1093/eurheartj/ehw377. Epub 2016 Aug 28.